Patient symptom surveys could cut chemo drug waste
NCT ID NCT04008056
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a 34-question symptom survey filled out by patients could give doctors enough information to authorize chemotherapy preparation, potentially reducing the number of unused drug doses. 138 people with digestive cancer participated. The goal was to see if the patient's report was as good as a doctor's exam for deciding to mix the chemo drugs.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Patient Reported Outcome questionnaire
- What this could lead to
- If successful, this could reduce wasted chemotherapy drugs by using patient symptom reports to authorize treatment preparation.
- What could go wrong
- This is a small, completed study focused on process efficiency, not a new treatment. Results may not apply to other cancers or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
138 people
The number who actually took part.
- Started
-
Nov 2019
- Finished
-
Dec 2021
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan * Patient is undergoing at least their second chemotherapy regime (outside weekly scheme or protocol with cisplatin requiring hospitalization) for a digestive tumor * Patient has a Smartphone or access to the internet (via tablet or computer) * The patient is under consultation as a day patient in the Oncology Department of Nimes hosptial Exclusion Criteria: * The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study * The subject refuses to sign the consent * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * The patient is pregnant, parturient or breastfeeding * Patient has already participated in the study * Patient undergoing first chemotherapy regime
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Digestive cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nimes
Nîmes, 30029, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cancer diagnosis can shock the whole family: study maps who struggles most
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Tailored chemo doses aim to cut severe side effects in digestive cancer patients
- New drug cocktail shows promise for tough bile duct cancer
- Steroid shot during surgery may cut cancer recovery risks